| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $10K | — | -99.7% |
| SG&A Expense | $3.1M | — | -40.3% |
| Operating Income | -$3.7M | — | +55.2% |
| Net Income | -$3.6M | — | +54.6% |
| EPS (Basic) | -$0.12 | — | +90.0% |
| EPS (Diluted) | -$0.12 | — | +90.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $10.1M | -43.9% | +45.5% |
| Current Assets | $13.2M | -27.6% | -52.3% |
| Total Assets | $113.3M | +519.8% | +308.4% |
| Current Liabilities | $1.1M | -21.1% | -62.8% |
| Total Liabilities | $1.1M | -21.1% | -62.8% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.5M | — | +60.6% |
| Investing Cash Flow | -$100.0M | — | -780.4% |
| Financing Cash Flow | $96.6M | — | — |
| $112.3M |
| +563.1% |
| +351.3% |